Bhanu Prasad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bhanu Prasad has a total of 414 co-authors. Here are the top co-authors by number of shared publications:
Kunal Goyal
Department of Radiology, Regina General Hospital, Regina, Canada
8 shared publications- Maryam Jafari
Dr. T. Bhanu Prasad Medical Professional Corporation, Regina, SK, Canada
8 shared publications Navdeep Tangri
Chronic Disease Innovation Centre, Seven Oaks General Hospital, University of Manitoba, Winnipeg, Manitoba, Canada
8 shared publicationsPouneh Dokouhaki
8 shared publicationsAditi Sharma
7 shared publications- Claudio Rigatto
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada
6 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Emergency Department Utilization after Initiation of Intermittent Hemodialysis: A Retrospective Cohort Study in Regina, Saskatchewan
Background: Emergency department (ED) use is common among patients with end-stage kidney disease (ESKD) initiating hemodialysis (HD), but potentially modifiable predictors of these visits remain poorly defined. Objective: To identify factors associated with ED visits among patients newly initiated on intermittent HD in Regina, Saskatchewan, Canada. Design: Retrospective cohort study. Setting: Regina General Hospital in Saskatchewan, Canada. Patients: 360 incident adult patients who received at least 90 days of HD between January 1, 2018, and December 31, 2022. Measurements: Patients were followed for one year from dialysis initiation to capture the number and causes of all-cause ED visits. Methods: Multinomial logistic regression was used to examine associations between patient characteristics and ED utilization, categorized as no visits, a single visit, 2–3 visits, or >3 visits, with no visits as the reference group. Results: Half of the cohort (n=180, 50%) had at least one ED visit during the first year, totaling 453 encounters. Gastrointestinal (GI) complaints were the most common reason for presentation (14.1%), followed by fluid overload (11.5%) and cardiovascular causes (8.3%). Dialysis non-adherence was independently associated with ED utilization across all categories, with the strongest association for >3 visits (RRR 7.34, 95% CI 2.81-19.20, p<0.001). Arteriovenous fistula use at dialysis initiation was associated with a lower risk of a single ED visit (RRR 0.28, 95% CI 0.09-0.90, p=0.033). In contrast, age, sex, diabetes, hypertension, and cardiovascular disease were not independently associated with ED utilization. Limitations: This single-center, retrospective study is limited by generalizability and could not analyze non-adherence factors. ED visits were grouped broadly, without assessing severity or preventability. Although ED visits were more frequent during the winter months, we did not examine whether missed dialysis treatments also varied by season. The study period from 2018 to 2022 overlaps with the COVID-19 pandemic, which may have affected ED utilization, dialysis attendance, outpatient access, and patient health-seeking behavior. This limits direct comparison with studies conducted entirely before or after the pandemic. Conclusions: Early ED utilization among incident HD patients may be reduced by improving dialysis adherence, ensuring timely permanent vascular access placement, and better management of GI symptoms.
- 8 September 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Open AccessEmergency Department Utilization after Initiation of Intermittent Hemodialysis: A Retrospective Cohort Study in Regina, Saskatchewan
Background: Emergency department (ED) use is common among patients with end-stage kidney disease (ESKD) initiating hemodialysis (HD), but potentially modifiable predictors of these visits remain poorly defined. Objective: To identify factors associated with ED visits among patients newly initiated on intermittent HD in Regina, Saskatchewan, Canada. Design: Retrospective cohort study. Setting: Regina General Hospital in Saskatchewan, Canada. Patients: 360 incident adult patients who received at least 90 days of HD between January 1, 2018, and December 31, 2022. Measurements: Patients were followed for one year from dialysis initiation to capture the number and causes of all-cause ED visits. Methods: Multinomial logistic regression was used to examine associations between patient characteristics and ED utilization, categorized as no visits, a single visit, 2–3 visits, or >3 visits, with no visits as the reference group. Results: Half of the cohort (n=180, 50%) had at least one ED visit during the first year, totaling 453 encounters. Gastrointestinal (GI) complaints were the most common reason for presentation (14.1%), followed by fluid overload (11.5%) and cardiovascular causes (8.3%). Dialysis non-adherence was independently associated with ED utilization across all categories, with the strongest association for >3 visits (RRR 7.34, 95% CI 2.81-19.20, p<0.001). Arteriovenous fistula use at dialysis initiation was associated with a lower risk of a single ED visit (RRR 0.28, 95% CI 0.09-0.90, p=0.033). In contrast, age, sex, diabetes, hypertension, and cardiovascular disease were not independently associated with ED utilization. Limitations: This single-center, retrospective study is limited by generalizability and could not analyze non-adherence factors. ED visits were grouped broadly, without assessing severity or preventability. Although ED visits were more frequent during the winter months, we did not examine whether missed dialysis treatments also varied by season. The study period from 2018 to 2022 overlaps with the COVID-19 pandemic, which may have affected ED utilization, dialysis attendance, outpatient access, and patient health-seeking behavior. This limits direct comparison with studies conducted entirely before or after the pandemic. Conclusions: Early ED utilization among incident HD patients may be reduced by improving dialysis adherence, ensuring timely permanent vascular access placement, and better management of GI symptoms.
- Open Access
- 9 February 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines
Purpose of review: The purpose of this commentary is to address the challenges of implementing the evolving Kidney Disease Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guidelines within the Canadian health care context, highlighting barriers to adoption of the guidelines and discussing contextual issues unique to Canada. Sources of information: The KDIGO 2021 guidelines with 2024 updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus nephritis, as well as the 2025 updated guideline for immunoglobulin A (IgA) nephropathy. Methods: A Canadian Society of Nephrology (CSN) working group with expertise in GN was formed, representing nephrologists, pathologists, pharmacists, and patient partners with geographic representation from across Canada. Recommendations and practice points were reviewed by member surveys, with discussions to reach consensus and frame the commentary. Key findings: The commentary highlights diagnostic investigations, the role of immune treatments for primary glomerular diseases, and the growing role of conservative kidney therapies. Limitations: A review of the quality of evidence was not undertaken. Implementation and uptake of the guidelines will vary across each province given drug availability and cost. Implications: The commentary aims to provide tailored guidance to enhance the care of Canadians living with glomerular disease.
- 9 February 2026
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 13
Open AccessCanadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines
Purpose of review: The purpose of this commentary is to address the challenges of implementing the evolving Kidney Disease Improving Global Outcomes (KDIGO) glomerulonephritis (GN) guidelines within the Canadian health care context, highlighting barriers to adoption of the guidelines and discussing contextual issues unique to Canada. Sources of information: The KDIGO 2021 guidelines with 2024 updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and lupus nephritis, as well as the 2025 updated guideline for immunoglobulin A (IgA) nephropathy. Methods: A Canadian Society of Nephrology (CSN) working group with expertise in GN was formed, representing nephrologists, pathologists, pharmacists, and patient partners with geographic representation from across Canada. Recommendations and practice points were reviewed by member surveys, with discussions to reach consensus and frame the commentary. Key findings: The commentary highlights diagnostic investigations, the role of immune treatments for primary glomerular diseases, and the growing role of conservative kidney therapies. Limitations: A review of the quality of evidence was not undertaken. Implementation and uptake of the guidelines will vary across each province given drug availability and cost. Implications: The commentary aims to provide tailored guidance to enhance the care of Canadians living with glomerular disease.
- Open Access
- 11 October 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (12)
Insights into Geographic Patterns, Urban-Rural Contrasts, and Health Care Disparities in Glomerular Disease Incidence in a Canadian Province
- 11 October 2025
- Published by Elsevier in Kidney Medicine
- Vol. 7 (12)
Open AccessInsights into Geographic Patterns, Urban-Rural Contrasts, and Health Care Disparities in Glomerular Disease Incidence in a Canadian Province
- 13 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1375-1386
Comparing Frailty Assessment Methods and Their Ability to Predict Adverse Outcomes in Patients with Advanced CKD
Key Points: Most measures of frailty, regardless of definition used, were associated with higher risk of mortality, hospitalizations, and emergency room visits. Claims-based definitions had poor agreement when compared with objective and subjective measures of frailty in the advanced CKD population. Administrative definitions require further development to accurately identify frail patients in the advanced CKD population. Background: Frailty is common in patients with CKD, and those affected by both are at increased risk of adverse outcomes including disability, hospitalization, and death. Collecting data on frailty as part of clinical care could enhance care by identifying patients at risk of adverse events. However, clinical assessment of frailty requires time and resources. Frailty definitions based on administrative data might provide an efficient alternative. The primary objective was to compare agreement between administrative claims-based definitions versus objectively measured frailty in adults with advanced, nondialysis CKD and to examine their associations with adverse outcomes. Methods: The cohort consisted of Manitoba participants from the Canadian Frailty Observation and Interventions Trial. This multicenter cohort study followed adults with advanced CKD longitudinally. Every visit, assessments were conducted to determine frailty status using the Fried Frailty Phenotype, Short Physical Performance Battery, and health care providers' impression. The Canadian Frailty Observation and Interventions Trial database was linked to administrative databases at the Manitoba Centre for Health Policy to calculate two claims-based frailty indicators, the Segal and modified preoperative frailty indices, which have been validated in the non-CKD literature. Results: Of the 442 participants included, the mean age was 66±14 years and 58% were male; 88% had hypertension, 61% dyslipidemia, and 58% diabetes. The prevalence of frailty varied from 19% to 70% depending on definition. Agreement between frailty definitions was poor ( κ 0.09–0.33); however, individuals considered frail using both administrative or measured definitions had a higher risk of all-cause mortality and hospitalization, except for those identified by the Segal Frailty Indicator. Conclusions: This study suggests that those identified as frail by nearly all measures were at higher risk of adverse outcomes. Thus, most frailty models in this study can be used to identify high risk advanced nondialysis CKD populations, allowing us to target individuals for interventions that aim to improve outcomes.
- 13 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (10) , 1375-1386
Comparing Frailty Assessment Methods and Their Ability to Predict Adverse Outcomes in Patients with Advanced CKD
Key Points: Most measures of frailty, regardless of definition used, were associated with higher risk of mortality, hospitalizations, and emergency room visits. Claims-based definitions had poor agreement when compared with objective and subjective measures of frailty in the advanced CKD population. Administrative definitions require further development to accurately identify frail patients in the advanced CKD population. Background: Frailty is common in patients with CKD, and those affected by both are at increased risk of adverse outcomes including disability, hospitalization, and death. Collecting data on frailty as part of clinical care could enhance care by identifying patients at risk of adverse events. However, clinical assessment of frailty requires time and resources. Frailty definitions based on administrative data might provide an efficient alternative. The primary objective was to compare agreement between administrative claims-based definitions versus objectively measured frailty in adults with advanced, nondialysis CKD and to examine their associations with adverse outcomes. Methods: The cohort consisted of Manitoba participants from the Canadian Frailty Observation and Interventions Trial. This multicenter cohort study followed adults with advanced CKD longitudinally. Every visit, assessments were conducted to determine frailty status using the Fried Frailty Phenotype, Short Physical Performance Battery, and health care providers' impression. The Canadian Frailty Observation and Interventions Trial database was linked to administrative databases at the Manitoba Centre for Health Policy to calculate two claims-based frailty indicators, the Segal and modified preoperative frailty indices, which have been validated in the non-CKD literature. Results: Of the 442 participants included, the mean age was 66±14 years and 58% were male; 88% had hypertension, 61% dyslipidemia, and 58% diabetes. The prevalence of frailty varied from 19% to 70% depending on definition. Agreement between frailty definitions was poor ( κ 0.09–0.33); however, individuals considered frail using both administrative or measured definitions had a higher risk of all-cause mortality and hospitalization, except for those identified by the Segal Frailty Indicator. Conclusions: This study suggests that those identified as frail by nearly all measures were at higher risk of adverse outcomes. Thus, most frailty models in this study can be used to identify high risk advanced nondialysis CKD populations, allowing us to target individuals for interventions that aim to improve outcomes.
- 6 April 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (2) , 288-291
Renal Denervation in Loin Pain Hematuria Syndrome: A Pilot Randomized Controlled Trial
- 6 April 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (2) , 288-291
Renal Denervation in Loin Pain Hematuria Syndrome: A Pilot Randomized Controlled Trial
- Open Access
- 3 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (4) , 636-644
CKD Progression after Acute Kidney Injury
Key Points: Development or progression of CKD occurred in almost 40% of patients after an episode of severe AKI. Receipt of KRT, regardless of allocation to an accelerated or standard initiation strategy, was associated with development or progression of CKD. This study helps identify a subset of patients at risk of CKD after severe AKI who would benefit from dedicated kidney follow-up after discharge. Background: CKD is a common complication after AKI. We aimed to evaluate whether a KRT initiation strategy had an effect on CKD progression. Secondarily, we aimed to identify factors that influenced the development or progression of CKD after severe AKI. Methods: This secondary analysis of the Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI trial included patients with outpatient serum creatinine values available in the year before hospitalization and who were alive at 90 days after randomization. Our main analysis focused on patients who had definitive assessment of kidney function at 90 days after randomization. Predictor markers included patient demographics, comorbidities, markers of acute illness, laboratory values, receipt of KRT, and KRT treatment strategy (accelerated versus standard). The primary outcome was CKD progression, a composite of de novo CKD, defined as new eGFR 2 if baseline eGFR was ≥60 ml/min; a decline in eGFR ≥25% if baseline eGFR was <60 ml/min; or KRT dependence at day 90. The association of KRT treatment strategy with CKD progression was assessed in an unadjusted mixed-effect logistic regression model. Results: Of the 401 surviving patients with a baseline serum creatinine, 39% experienced CKD progression. KRT initiation strategy had no effect on CKD progression (accelerated arm [41%], versus the standard arm [38%], odds ratio, 1.13 [95% confidence interval, 0.75 to 1.72]). Receipt of KRT and aortic surgery were the most potent risks of CKD progression. Conclusions: These findings suggest that CKD progression is common after severe AKI. Risk factors of CKD progression included receipt of KRT and aortic surgery, suggesting that these patients should be prioritized for dedicated kidney follow-up after hospital discharge. Clinical Trial registry name and registration number: NCT01557361.
- 3 December 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (4) , 636-644
Open AccessCKD Progression after Acute Kidney Injury
Key Points: Development or progression of CKD occurred in almost 40% of patients after an episode of severe AKI. Receipt of KRT, regardless of allocation to an accelerated or standard initiation strategy, was associated with development or progression of CKD. This study helps identify a subset of patients at risk of CKD after severe AKI who would benefit from dedicated kidney follow-up after discharge. Background: CKD is a common complication after AKI. We aimed to evaluate whether a KRT initiation strategy had an effect on CKD progression. Secondarily, we aimed to identify factors that influenced the development or progression of CKD after severe AKI. Methods: This secondary analysis of the Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI trial included patients with outpatient serum creatinine values available in the year before hospitalization and who were alive at 90 days after randomization. Our main analysis focused on patients who had definitive assessment of kidney function at 90 days after randomization. Predictor markers included patient demographics, comorbidities, markers of acute illness, laboratory values, receipt of KRT, and KRT treatment strategy (accelerated versus standard). The primary outcome was CKD progression, a composite of de novo CKD, defined as new eGFR 2 if baseline eGFR was ≥60 ml/min; a decline in eGFR ≥25% if baseline eGFR was <60 ml/min; or KRT dependence at day 90. The association of KRT treatment strategy with CKD progression was assessed in an unadjusted mixed-effect logistic regression model. Results: Of the 401 surviving patients with a baseline serum creatinine, 39% experienced CKD progression. KRT initiation strategy had no effect on CKD progression (accelerated arm [41%], versus the standard arm [38%], odds ratio, 1.13 [95% confidence interval, 0.75 to 1.72]). Receipt of KRT and aortic surgery were the most potent risks of CKD progression. Conclusions: These findings suggest that CKD progression is common after severe AKI. Risk factors of CKD progression included receipt of KRT and aortic surgery, suggesting that these patients should be prioritized for dedicated kidney follow-up after hospital discharge. Clinical Trial registry name and registration number: NCT01557361.
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (5) , 901-910
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis
Key Points: Is performing a large definitive trial to establish the optimal anticoagulation strategy in dialysis recipients with atrial fibrillation feasible? One hundred fifty-one patients at 28 dialysis centers were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Despite coronavirus disease–related pauses, recruitment was completed in 30 months, with 83% of participants completing follow-up in their assigned treatment arm. Background: Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. Methods: The Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis trial was a parallel-group, open-label, allocation-concealed, pilot randomized control trial that took place at 28 centers in Canada and Australia. The trial included adults (18 years or older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 criteria. Participants were randomized 1:1:1 to receive dose-adjusted warfarin, apixaban 5 mg twice daily, or no oral anticoagulation and followed for 26 weeks. The primary outcomes evaluated the following measures of feasibility: ( 1 ) recruitment of the target population within 2 years from the start of the trial and ( 2 ) adherence of >80% of randomized patients to the allocated treatment strategy at the conclusion of follow-up. Secondary outcomes included stroke and bleeding. Results: From December 2019 to June 2022, 151 patients were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Allowing for pauses related to the coronavirus disease pandemic, recruitment was completed in 30 months, and 123 (83%) of participants completed follow-up in their allocated treatment arm. There was one adjudicated stroke event. Eight participants had a major bleeding event (four warfarin, two apixaban, two no oral anticoagulation). Death occurred in 15 participants (nine warfarin, two apixaban, four no oral anticoagulation). Time in the therapeutic range for warfarin recipients was 58% (interquartile range, 47%–70%). Conclusions: We have demonstrated the feasibility of recruitment and adherence in a trial that compared different anticoagulation strategies in patients with atrial fibrillation receiving dialysis. Clinical Trial registry name and registration number: Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis (SAFE-D), NCT03987711. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3
- 4 November 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (5) , 901-910
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis
Key Points: Is performing a large definitive trial to establish the optimal anticoagulation strategy in dialysis recipients with atrial fibrillation feasible? One hundred fifty-one patients at 28 dialysis centers were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Despite coronavirus disease–related pauses, recruitment was completed in 30 months, with 83% of participants completing follow-up in their assigned treatment arm. Background: Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. Methods: The Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis trial was a parallel-group, open-label, allocation-concealed, pilot randomized control trial that took place at 28 centers in Canada and Australia. The trial included adults (18 years or older) undergoing dialysis with a history of nonvalvular atrial fibrillation who met the CHADS-65 criteria. Participants were randomized 1:1:1 to receive dose-adjusted warfarin, apixaban 5 mg twice daily, or no oral anticoagulation and followed for 26 weeks. The primary outcomes evaluated the following measures of feasibility: ( 1 ) recruitment of the target population within 2 years from the start of the trial and ( 2 ) adherence of >80% of randomized patients to the allocated treatment strategy at the conclusion of follow-up. Secondary outcomes included stroke and bleeding. Results: From December 2019 to June 2022, 151 patients were enrolled and randomized to apixaban ( n =51), warfarin ( n =52), or no oral anticoagulation ( n =48). Allowing for pauses related to the coronavirus disease pandemic, recruitment was completed in 30 months, and 123 (83%) of participants completed follow-up in their allocated treatment arm. There was one adjudicated stroke event. Eight participants had a major bleeding event (four warfarin, two apixaban, two no oral anticoagulation). Death occurred in 15 participants (nine warfarin, two apixaban, four no oral anticoagulation). Time in the therapeutic range for warfarin recipients was 58% (interquartile range, 47%–70%). Conclusions: We have demonstrated the feasibility of recruitment and adherence in a trial that compared different anticoagulation strategies in patients with atrial fibrillation receiving dialysis. Clinical Trial registry name and registration number: Strategies for the Management of Atrial Fibrillation in Patients Receiving Dialysis (SAFE-D), NCT03987711. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2025_04_09_ASN0000000000000495.mp3
- Open Access
- 1 January 2024
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 11
Five Things to Know About Depression in Hemodialysis
- 1 January 2024
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 11
Open AccessFive Things to Know About Depression in Hemodialysis
- Open Access
- 1 January 2024
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 11
Pathways for Diagnosing and Treating CKD-Associated Pruritus: A Narrative Review
Purpose of Review: Chronic kidney disease (CKD)-associated pruritus is a common, persistent, and distressing itch experienced by patients across the CKD spectrum. Although the disorder is associated with adverse outcomes and poor health-related quality of life, it remains underdiagnosed and undertreated. The purpose of this narrative review is to offer health care providers guidance on how to effectively identify, assess, and treat patients with CKD-associated pruritus, with the goal of reducing symptom burden and improving patient-important outcomes, such as quality of life (QoL). Sources of Information: A panel of nephrologists and researchers from across Canada and the United States was assembled to develop this narrative review based on the best available data, current treatment guidelines, and their clinical experiences. Methods: A panel of nephrologists who actively care for patients with pruritus receiving dialysis from across Canada was assembled. Two researchers from the United States were also included based on their expertise in the diagnosis and management of CKD-associated pruritus. Throughout Spring 2023, the panel met to discuss key topics in the identification, assessment, and management of CKD-associated pruritus. Panel members subsequently developed summaries of the pertinent information based on the best available data, current treatment guidelines, and added information on their own clinical experiences. In all cases, approval of the article was sought and achieved through discussion. Key Findings: This narrative review provides pragmatic guidance addressing: (1) methods for screening CKD-associated pruritus, (2) assessing severity, (3) management of CKD-associated pruritus, and (4) suggested areas for future research. The panel developed a 3-pillar framework for proactive assessment and severity scoring in CKD-aP: systematic screening for CKD-associated pruritus (pillar 1), assessment of pruritus intensity (pillar 2), and understanding the impact of CKD-associated pruritus on the patient’s QoL (pillar 3). Management of CKD-associated pruritus can include ensuring optimization of dialysis adequacy, achieving mineral metabolism targets (ie, calcium, phosphate, and parathyroid hormone). However, treatment of CKD-associated pruritus usually requires additional interventions. Patients, regardless of CKD-associated pruritus severity, should be counseled on adequate skin hydration and other non-pharmacological strategies to reduce pruritus. Antihistamines should be avoided in favor of evidence-based treatments, such as difelikefalin and gabapentin. Limitations: A formal systematic review (SR) of the literature was not undertaken, although published SRs were reviewed. The possibility for bias based on the experts’ own clinical experiences may have occurred. Key takeaways are based on the current available evidence, of which head-to-head clinical trials are lacking. Funding: This work was funded by an arm’s length grant from Otsuka Canada Pharmaceutical Inc. (the importer and distributer of difelikefalin in Canada). LiV Medical Education Agency Inc. provided logistical and editorial support.
- 1 January 2024
- Published by SAGE Publications in Canadian Journal of Kidney Health and Disease
- Vol. 11
Open AccessPathways for Diagnosing and Treating CKD-Associated Pruritus: A Narrative Review
Purpose of Review: Chronic kidney disease (CKD)-associated pruritus is a common, persistent, and distressing itch experienced by patients across the CKD spectrum. Although the disorder is associated with adverse outcomes and poor health-related quality of life, it remains underdiagnosed and undertreated. The purpose of this narrative review is to offer health care providers guidance on how to effectively identify, assess, and treat patients with CKD-associated pruritus, with the goal of reducing symptom burden and improving patient-important outcomes, such as quality of life (QoL). Sources of Information: A panel of nephrologists and researchers from across Canada and the United States was assembled to develop this narrative review based on the best available data, current treatment guidelines, and their clinical experiences. Methods: A panel of nephrologists who actively care for patients with pruritus receiving dialysis from across Canada was assembled. Two researchers from the United States were also included based on their expertise in the diagnosis and management of CKD-associated pruritus. Throughout Spring 2023, the panel met to discuss key topics in the identification, assessment, and management of CKD-associated pruritus. Panel members subsequently developed summaries of the pertinent information based on the best available data, current treatment guidelines, and added information on their own clinical experiences. In all cases, approval of the article was sought and achieved through discussion. Key Findings: This narrative review provides pragmatic guidance addressing: (1) methods for screening CKD-associated pruritus, (2) assessing severity, (3) management of CKD-associated pruritus, and (4) suggested areas for future research. The panel developed a 3-pillar framework for proactive assessment and severity scoring in CKD-aP: systematic screening for CKD-associated pruritus (pillar 1), assessment of pruritus intensity (pillar 2), and understanding the impact of CKD-associated pruritus on the patient’s QoL (pillar 3). Management of CKD-associated pruritus can include ensuring optimization of dialysis adequacy, achieving mineral metabolism targets (ie, calcium, phosphate, and parathyroid hormone). However, treatment of CKD-associated pruritus usually requires additional interventions. Patients, regardless of CKD-associated pruritus severity, should be counseled on adequate skin hydration and other non-pharmacological strategies to reduce pruritus. Antihistamines should be avoided in favor of evidence-based treatments, such as difelikefalin and gabapentin. Limitations: A formal systematic review (SR) of the literature was not undertaken, although published SRs were reviewed. The possibility for bias based on the experts’ own clinical experiences may have occurred. Key takeaways are based on the current available evidence, of which head-to-head clinical trials are lacking. Funding: This work was funded by an arm’s length grant from Otsuka Canada Pharmaceutical Inc. (the importer and distributer of difelikefalin in Canada). LiV Medical Education Agency Inc. provided logistical and editorial support.